<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">TORSEMIDE</span><br/>(tor'se-mide)<br/><span class="topboxtradename">Demadex<br/></span><b>Classifications:</b> <span class="classification">electrolyte and water balance agent</span>; <span class="classification">loop diuretic</span><br/><b>Prototype: </b>Furosemide<br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>5 mg, 10 mg, 20 mg, 100 mg tablets; 10 mg/mL injection</p>
<h1><a name="action">Actions</a></h1>
<p>Long-acting potent sulfonamide "loop" diuretic that inhibits reabsorption of sodium and chloride primarily in the
         loop of Henle and also in the proximal and distal renal tubules. Binds to the sodium/potassium/chloride carrier in the loop
         of Henle and in the renal tubules. Lower potassium-wasting effects than furosemide and a longer half-life.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Long-acting potent sulfonamide "loop" diuretic and antihypertensive agent.</p>
<h1><a name="uses">Uses</a></h1>
<p>Management of edema associated with CHF, chronic kidney failure, hepatic cirrhosis; hypertension.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to torsemide or sulfonamides; anuria, fluid and electrolyte depletion states; hepatic coma; pregnancy (category
         B).
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Renal impairment; concurrent use of other ototoxic drugs; gout or hyperuricemia; diabetes mellitus or history of pancreatitis;
         liver disease; hearing impairment; lactation.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">CHF, Chronic Kidney Failure</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO/IV</span> 1020 mg once daily, may increase up to 200 mg/d as needed<br/><br/><span class="indicationtitle">Hepatic Cirrhosis</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO/IV</span> 510 mg once daily administered with an aldosterone antagonist or potassium-sparing diuretic, may increase up to 40 mg/d
               as needed<br/><br/><span class="indicationtitle">Hypertension</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO/IV</span> 5 mg once daily, may increase to 10 mg/d if no response after 46 wk<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1>
<ul>
<li>
            				Note: With hepatic cirrhosis, use an aldosterone antagonist concomitantly to prevent hypokalemia and metabolic alkalosis.
            			
         </li>
</ul><span class="adminroutetype">Oral</span><br/><ul>
<li>Be aware that oral and IV doses are therapeutically equivalent; patients may be switched between the two forms with no change
            in dosage.
         </li>
</ul>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><p><span class="routemethod">PREPARE:</span> <span class="methodtype">Direct:</span> Given undiluted.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">Direct:</span> Give slowly over 2 min.  
               </p>
</td>
</tr>
</table>
<ul>
<li>Store at 15°30° C (59°86° F).</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> Headache, dizziness, fatigue, insomnia. <span class="typehead">CV:</span> Orthostatic hypotension. <span class="typehead">Endocrine:</span>
<span class="speceff-common">Hypokalemia,</span> hyponatremia, hyperuricemia. <span class="typehead">GI:</span> Nausea, diarrhea. <span class="typehead">Skin:</span> Rash, pruritus. <span class="typehead">Body as a Whole:</span> Muscle cramps, rhinitis. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<span class="classification">nsaid</span>s may reduce diuretic effects. Also see furosemide for potential drug interactions such as increased risk of <b>digoxin</b> toxicity due to hypokalemia, prolonged neuromuscular blockade with <span class="classification">neuromuscular blocking agents</span>, and decreased <b>lithium</b> elimination with increased toxicity. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Readily absorbed from GI tract. <span class="typehead">Onset:</span> IV 10 min; PO 60 min. <span class="typehead">Peak:</span> IV within 60 min; PO 60120 min. <span class="typehead">Duration:</span> 68 h. <span class="typehead">Metabolism:</span> Metabolized in liver by cytochrome P450 system. <span class="typehead">Elimination:</span> 80% excreted in bile; 20% excreted in urine. <span class="typehead">Half-Life:</span> 210 min. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor BP often and assess for orthostatic hypotension; periodically assess weight as an index of fluid retention.</li>
<li>Lab tests: Monitor serum electrolytes, uric acid, blood glucose, BUN, and creatinine periodically throughout the course of
            therapy.
         </li>
<li>Monitor coagulation parameters and lithium levels in patients on concurrent anticoagulant and/or lithium therapy.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Check weight at least weekly and report abrupt gains or losses to physician.</li>
<li>Understand the risk of orthostatic hypotension.</li>
<li>Report symptoms of hypokalemia (see Appendix F) or hearing loss immediately to physician.</li>
<li>Monitor blood glucose for loss of glycemic control if diabetic.</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>